

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 6, 2nd Floor Library**

October 23, 2013

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for June 26, 2013 meeting (pages 3-10; Tab 1)
- IV. Secretary's report (pages 11; Tab 2)
- V. Old Business
 - A. HMO response to DURB follow-up questions regarding protocols (pages 13-15; Tab 3)
- VI. New Business
 - A. Educational newsletter for long-acting beta-agonists (pages 17-19; Tab 4)
 - B. Protocols review (pages 21 - 53; Tab 5)
 1. Biologic response modifiers (pages 21-27)
 2. Dronedarone (Multaq[®]) (pages 28-30)
 3. Human growth hormones (pages 31-45)
 4. Palivizumab (Synagis[®]) (pages 46-49)
 5. Protease inhibitors for hepatitis C treatment (pages 50-53)
- VII. Informational Highlights/Reports
 1. Molina Prior Authorization Report (pages 55-57; Tab 6)
 2. NJ HMO Reports 2nd Quarter 2013 (pages 58-61; Tab 6)
 3. Summary of DURB Action Items (pages 63; Tab 7)
 4. DHS and DHSS Programs Top Drugs Report (pages 65-77; Tab 8)
 5. Medication information: (pages 79-84; Tab 9)
 - (a) NJ Prescription Monitoring Program
 - (b) New APA guidelines on cutting antipsychotic overuse
 - (c) FDA approves new DPP-4 Inhibitor alogliptin (Nesina[®]) for T2DM
 - (d) FDA Approves dolutegravir (Tivicay[®]) for HIV infection